For the year ending 2025-12-31, VYGR made $40,374K in revenue. -$119,282K in net income. Net profit margin of -295.44%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Collaboration revenue | 40,374 | |||
| Research and development | 134,674 | |||
| General and administrative | 37,544 | |||
| Total operating expenses | 172,218 | |||
| Operating (loss) income | -131,844 | |||
| Interest income | 10,618 | |||
| Other income | 1,649 | |||
| Total other income, net | 12,267 | |||
| (loss) income before income taxes | -119,577 | |||
| Income tax provision | 144 | |||
| Net (loss) income | -119,721 | |||
| Net unrealized gain (loss) on available-for-sale-securities | 439 | |||
| Total other comprehensive income (loss) | 439 | |||
| Comprehensive income (loss) | -119,282 | |||
| Basic EPS | -2.04 | |||
| Diluted EPS | -2.04 | |||
| Basic Average Shares | 58,691,136 | |||
| Diluted Average Shares | 58,691,136 | |||
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)